Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Invus
AddedFeb 13, 2024
UpdatedJul 11, 2026
Invus

Invus

Operating

Invus, a unique business transformer, aligns with partners for long-term success, managing over $4B globally since 1985.

Location
New York City, NY, US
Founded
1985
Firm
Compare
Portfolio
Employees
Website

Investments

Flare Therapeutics
Flare Therapeutics
Series C

Total Raised

$290M

Rounds

3

Series C$85MJune 2026
Series B$123MMarch 2023
City Therapeutics
City Therapeutics
Series B

Total Raised

$234.5M

Rounds

2

Series B$99.5MJune 2026
Series A$135MOctober 2024
Syros Pharmaceuticals
Syros Pharmaceuticals
Public

Total Raised

$620.5M

Rounds

12

Post Ipo Equity$45MDecember 2023
Bicara Therapeutics
Bicara Therapeutics

Total Raised

$313M

Rounds

3

Series C$165MDecember 2023
Series B$108MMarch 2023
Triveni Bio
Triveni Bio
Series C

Total Raised

$272M

Rounds

3

Series A$92MOctober 2023
Health Data Analytics Institute
Health Data Analytics Institute

Total Raised

$47M

Rounds

2

Series C$31MOctober 2023
PayJoy
PayJoy

Total Raised

$407.1M

Rounds

9

Series C$150MSeptember 2023
Taysha Gene Therapies
Taysha Gene Therapies
Public

Total Raised

$468M

Rounds

8

Post Ipo Equity$150MAugust 2023
Adarx Pharmaceuticals
Adarx Pharmaceuticals

Total Raised

$332M

Rounds

5

Series C$200MAugust 2023
Tisento Therapeutics
Tisento Therapeutics

Total Raised

$91M

Rounds

2

Series A$81MJuly 2023
Septerna
Septerna

Total Raised

$250M

Rounds

2

Series B$150MJuly 2023
ElevateBio
ElevateBio

Total Raised

$1.2B

Rounds

5

Series D$401MMay 2023
Convergent Therapeutics
Convergent Therapeutics

Total Raised

$90M

Rounds

1

Series A$90MMay 2023
Orbital Therapeutics
Orbital Therapeutics

Total Raised

$270M

Rounds

2

Series A$270MApril 2023
Ring Therapeutics
Ring Therapeutics

Total Raised

$253.5M

Rounds

3

Series C$86.5MMarch 2023
NextPoint Therapeutics
NextPoint Therapeutics

Total Raised

$80M

Rounds

1

Series B$80MJanuary 2023
Fog Pharmaceuticals
Fog Pharmaceuticals

Total Raised

$385.3M

Rounds

5

Series D$178MNovember 2022
Recursion Pharmaceuticals
Recursion Pharmaceuticals
Public

Total Raised

$665.4M

Rounds

19

Post Ipo Equity$150MOctober 2022
Solid Biosciences
Solid Biosciences
Public

Total Raised

$441.3M

Rounds

8

Post Ipo Equity$75MSeptember 2022
Pretzel Therapeutics
Pretzel Therapeutics

Total Raised

$72.5M

Rounds

2

Series A$72.5MSeptember 2022
Autobahn Therapeutics
Autobahn Therapeutics

Total Raised

$108.7M

Rounds

2

Series Unknown$32.7MSeptember 2022
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals
Public

Total Raised

$563.6M

Rounds

11

Post Ipo Equity$42.9MJuly 2022